Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous progenitor expansion -T
- Development stage
- Unknown
- Lead developer
- Shanghai Pudong Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intracavitary, Intrathecal
01
Overview
Autologous progenitor expansion -T, also known as RAK cells (Receptor-Activated Killer cells), is an autologous cell therapy developed by Shanghai Pudong Hospital for the treatment of primary and metastatic brain tumors. The therapy involves the expansion of a patient's own progenitor cells into 'bi-dimensional specific' T cells, which are then administered locally via a percutaneous Ommaya capsule directly into the tumor cavity or the cerebrospinal fluid. This localized delivery method is designed to bypass the blood-brain barrier and concentrate the therapeutic effect within the central nervous system. In clinical trials, the cells are administered weekly, often in conjunction with interleukin-2 (IL-2) to support their survival and activity, and may be combined with intrathecal pemetrexed for patients with brain or meningeal metastases from solid tumors.
- Other names
- Autologous bi-dimensional specific T cellsReceptor-Activated Killer cellsAutologous bi-dimensional specific T-cells
Beyond the preview
Go deeper on Autologous progenitor expansion -T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous progenitor expansion -T.